{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T05:04:16Z","timestamp":1794459856522,"version":"4.9.1"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T00:00:00Z","timestamp":1706313600000},"content-version":"vor","delay-in-days":1152,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T00:00:00Z","timestamp":1668211200000},"content-version":"vor","delay-in-days":711,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ascendis Pharma Bone Diseases A\/S, Hellerup, Denmark"}],"content-domain":{"domain":["asbmr.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Conventional therapy for hypoparathyroidism consisting of active vitamin D and calcium aims to alleviate hypocalcemia but fails to restore normal parathyroid hormone (PTH) physiology. PTH replacement therapy is the ideal physiologic treatment for hypoparathyroidism. The double-blind, placebo-controlled, 26-week, phase 3 PaTHway trial assessed the efficacy and safety of PTH replacement therapy for hypoparathyroidism individuals with the investigational drug TransCon PTH (palopegteriparatide). Participants (n\u00a0=\u00a084) were randomized 3:1 to once-daily TransCon PTH (initially 18\u2009\u03bcg\/d) or placebo, both co-administered with conventional therapy. The study drug and conventional therapy were titrated according to a dosing algorithm guided by serum calcium. The composite primary efficacy endpoint was the proportion of participants at week 26 who achieved normal albumin-adjusted serum calcium levels (8.3\u201310.6\u00a0mg\/dL), independence from conventional therapy (requiring no active vitamin D and \u2264600\u2009mg\/d of calcium), and no increase in study drug over 4\u2009weeks before week 26. Other outcomes of interest included health-related quality of life measured by the 36-Item Short Form Survey (SF-36), hypoparathyroidism-related symptoms, functioning, and well-being measured by the Hypoparathyroidism Patient Experience Scale (HPES), and urinary calcium excretion. At week 26, 79% (48\/61) of participants treated with TransCon PTH versus 5% (1\/21) wiplacebo met the composite primary efficacy endpoint (p\u2009&amp;lt;\u20090.0001). TransCon PTH treatment demonstrated a significant improvement in all key secondary endpoint HPES domain scores (all p\u2009&amp;lt;\u20090.01) and the SF-36 Physical Functioning subscale score (p\u00a0=\u00a00.0347) compared with placebo. Additionally, 93% (57\/61) of participants treated with TransCon PTH achieved independence from conventional therapy. TransCon PTH treatment normalized mean 24-hour urine calcium. Overall, 82% (50\/61) treated with TransCon PTH and 100% (21\/21) wiplacebo experienced adverse events; most were mild (46%) or moderate (46%). No study drug-related withdrawals occurred. In conclusion, TransCon PTH maintained normocalcemia while permitting independence from conventional therapy and was well-tolerated in individuals with hypoparathyroidism. \u00a9 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).<\/jats:p>\n                  <jats:p>Abstract<\/jats:p>\n                  <jats:p>TransCon PTH is an investigational once-daily prodrug providing sustained release of active PTH designed to maintain stable PTH levels in the physiological range for 24 hours\/day. The PaTHway trial met all primary and key secondary endpoints with statistically significant differences from placebo. Most adverse events (AEs) were mild\/moderate. Injection-site reactions and headaches were the most common treatment-related AEs.<\/jats:p>","DOI":"10.1002\/jbmr.4726","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T23:38:47Z","timestamp":1666395527000},"page":"14-25","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":116,"title":["Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the Phase 3 PaTHway Trial"],"prefix":"10.1093","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3733-8956","authenticated-orcid":false,"given":"Aliya A","family":"Khan","sequence":"first","affiliation":[{"name":"Endocrinology, Metabolism, and Geriatrics McMaster University Hamilton Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mishaela R","family":"Rubin","sequence":"additional","affiliation":[{"name":"Endocrinology Columbia University New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0483-8594","authenticated-orcid":false,"given":"Peter","family":"Schwarz","sequence":"additional","affiliation":[{"name":"Internal Medicine and Endocrinology Rigshospitalet Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Vokes","sequence":"additional","affiliation":[{"name":"Endocrinology, Diabetes, and Metabolism University of Chicago Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores M","family":"Shoback","sequence":"additional","affiliation":[{"name":"Endocrinology UCSF\/VA Medical Center San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9623-962X","authenticated-orcid":false,"given":"Claudia","family":"Gagnon","sequence":"additional","affiliation":[{"name":"CHU de Qu\u00e9bec-Universit\u00e9 Laval Research Centre and Department of Medicine Universit\u00e9 Laval Quebec City Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1143-4926","authenticated-orcid":false,"given":"Andrea","family":"Palermo","sequence":"additional","affiliation":[{"name":"Unit of Metabolic Bone and Thyroid Disorders, Fondazione Policlinico Campus Bio-medico, and Unit of Endocrinology and Diabetes Campus Bio-medico University Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6568-8588","authenticated-orcid":false,"given":"Claudio","family":"Marcocci","sequence":"additional","affiliation":[{"name":"Endocrinology University di Pisa Pisa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3801-9546","authenticated-orcid":false,"given":"Bart L","family":"Clarke","sequence":"additional","affiliation":[{"name":"Endocrinology Mayo Clinic E18-A Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa G","family":"Abbott","sequence":"additional","affiliation":[{"name":"Northern Nevada Endocrinology University of Nevada Reno Nevada USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz C","family":"Hofbauer","sequence":"additional","affiliation":[{"name":"Endocrinology, Diabetes, and Metabolic Bone Diseases Technische Universit\u00e4t Dresden Medical Center Dresden Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Kohlmeier","sequence":"additional","affiliation":[{"name":"Endocrinology Endocrinology and Spokane Osteoporosis Spokane Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Pihl","sequence":"additional","affiliation":[{"name":"Biolanalysis and Pharmacokinetics\/Pharmacodynamics Ascendis Pharma A\/S Hellerup Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuebei","family":"An","sequence":"additional","affiliation":[{"name":"Endocrine Medical Sciences Ascendis Pharma Inc Palo Alto California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter Frank","family":"Eng","sequence":"additional","affiliation":[{"name":"Endocrine Medical Sciences Ascendis Pharma Inc Palo Alto California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alden R","family":"Smith","sequence":"additional","affiliation":[{"name":"Endocrine Medical Sciences Ascendis Pharma Inc Palo Alto California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Ukena","sequence":"additional","affiliation":[{"name":"Endocrine Medical Sciences Ascendis Pharma Inc Palo Alto California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher T","family":"Sibley","sequence":"additional","affiliation":[{"name":"Endocrine Medical Sciences Ascendis Pharma Inc Palo Alto California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1801-5289","authenticated-orcid":false,"given":"Aimee D","family":"Shu","sequence":"additional","affiliation":[{"name":"Endocrine Medical Sciences Ascendis Pharma Inc Palo Alto California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Rejnmark","sequence":"additional","affiliation":[{"name":"Clinical Medicine and Endocrinology Aarhus University Hospital Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,10,21]]},"reference":[{"issue":"6","key":"2024012714090724500_jbmr4726-bib-0001","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1210\/jc.2015-3909","article-title":"Presentation of hypoparathyroidism: etiologies and clinical features","volume":"101","author":"Shoback","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2024012714090724500_jbmr4726-bib-0002","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1210\/jc.2015-3910","article-title":"Management of hypoparathyroidism: present and future","volume":"101","author":"Bilezikian","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2024012714090724500_jbmr4726-bib-0003","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1210\/jc.2015-3907","article-title":"Management of hypoparathyroidism: summary statement and guidelines","volume":"101","author":"Brandi","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2024012714090724500_jbmr4726-bib-0004","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1530\/eje.0.1460215","article-title":"Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D","volume":"146","author":"Arlt","year":"2002","journal-title":"Eur J Endocrinol."},{"issue":"6","key":"2024012714090724500_jbmr4726-bib-0005","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1210\/jc.2013-1239","article-title":"The effect of PTH(1-84) on quality of life in hypoparathyroidism","volume":"98","author":"Cusano","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2024012714090724500_jbmr4726-bib-0006","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1210\/clinem\/dgaa113","article-title":"Hypoparathyroidism","volume":"105","author":"Bilezikian","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2024012714090724500_jbmr4726-bib-0007","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s12020-017-1377-3","article-title":"Quality of life in patients with hypoparathyroidism receiving standard treatment: a systematic review","volume":"58","author":"Buttner","year":"2017","journal-title":"Endocrine."},{"issue":"7","key":"2024012714090724500_jbmr4726-bib-0008","doi-asserted-by":"crossref","first-page":"671","DOI":"10.4158\/EP13328.OR","article-title":"Understanding the burden of illness associated with hypoparathyroidism reported among patients in the PARADOX study","volume":"20","author":"Hadker","year":"2014","journal-title":"Endocr Pract."},{"issue":"8","key":"2024012714090724500_jbmr4726-bib-0009","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1210\/jc.2016-1477","article-title":"Epidemiology and health-related quality of life in hypoparathyroidism in Norway","volume":"101","author":"Astor","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2024012714090724500_jbmr4726-bib-0010","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/cen.14128","article-title":"Burden of illness in not adequately controlled chronic hypoparathyroidism: findings from a 13-country patient and caregiver survey","volume":"92","author":"Siggelkow","year":"2020","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"12","key":"2024012714090724500_jbmr4726-bib-0011","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1210\/jc.2012-1808","article-title":"Long-term follow-up of patients with hypoparathyroidism","volume":"97","author":"Mitchell","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2024012714090724500_jbmr4726-bib-0012","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.ecl.2018.07.001","article-title":"Signs and symptoms of hypoparathyroidism","volume":"47","author":"Cusano","year":"2018","journal-title":"Endocrinol Metab Clin North Am."},{"issue":"1","key":"2024012714090724500_jbmr4726-bib-0013","doi-asserted-by":"crossref","first-page":"e372","DOI":"10.1210\/clinem\/dgab577","article-title":"PaTH forward: a randomized, double-blind, placebo-controlled phase 2 trial of TransCon PTH in adult hypoparathyroidism","volume":"107","author":"Khan","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2024012714090724500_jbmr4726-bib-0014","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.beem.2014.09.001","article-title":"Parathyroid hormone therapy for hypoparathyroidism","volume":"29","author":"Cusano","year":"2015","journal-title":"Best Pract Res Clin Endocrinol Metab."},{"issue":"10","key":"2024012714090724500_jbmr4726-bib-0015","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1002\/jbmr.483","article-title":"Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research","volume":"26","author":"Bilezikian","year":"2011","journal-title":"J Bone Miner Res."},{"issue":"4","key":"2024012714090724500_jbmr4726-bib-0016","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(13)70106-2","article-title":"Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study","volume":"1","author":"Mannstadt","year":"2013","journal-title":"Lancet Diabetes Endocrinol."},{"key":"2024012714090724500_jbmr4726-bib-0017","author":"Center for Drug Evaluation and Research","year":"2014"},{"issue":"2","key":"2024012714090724500_jbmr4726-bib-0018","first-page":"391","article-title":"Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism","volume":"97","author":"Winer","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"issue":"11","key":"2024012714090724500_jbmr4726-bib-0019","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1002\/jbmr.3824","article-title":"Design and preclinical development of TransCon PTH, an investigational sustained-release PTH replacement therapy for hypoparathyroidism","volume":"34","author":"Holten-Andersen","year":"2019","journal-title":"J Bone Miner Res."},{"issue":"8","key":"2024012714090724500_jbmr4726-bib-0020","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/jbmr.4016","article-title":"A randomized double-blind placebo-controlled first-in-human phase 1 trial of TransCon PTH in healthy adults","volume":"35","author":"Karpf","year":"2020","journal-title":"J Bone Miner Res."},{"issue":"1","key":"2024012714090724500_jbmr4726-bib-0021","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s41687-021-00320-2","article-title":"Psychometric validation of the hypoparathyroidism patient experience scales (HPES)","volume":"5","author":"Brod","year":"2021","journal-title":"J Patient Rep Outcomes"},{"issue":"2","key":"2024012714090724500_jbmr4726-bib-0022","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1210\/jc.2017-01471","article-title":"Recombinant human parathyroid hormone effect on health-related quality of life in adults with chronic hypoparathyroidism","volume":"103","author":"Vokes","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"2024012714090724500_jbmr4726-bib-0023","doi-asserted-by":"crossref","first-page":"17055","DOI":"10.1038\/nrdp.2017.55","article-title":"Hypoparathyroidism","volume":"3","author":"Mannstadt","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"2024012714090724500_jbmr4726-bib-0024","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.bone.2018.09.017","article-title":"Quality of life in hypoparathyroidism","volume":"120","author":"Vokes","year":"2019","journal-title":"Bone."},{"issue":"9","key":"2024012714090724500_jbmr4726-bib-0025","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1210\/jc.2002-021736","article-title":"Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium","volume":"88","author":"Winer","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"issue":"10","key":"2024012714090724500_jbmr4726-bib-0026","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1210\/jc.2014-2267","article-title":"PTH(1-84) is associated with improved quality of life in hypoparathyroidism through 5\u2009years of therapy","volume":"99","author":"Cusano","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2024012714090724500_jbmr4726-bib-0027","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1210\/jc.2015-3908","article-title":"Epidemiology and diagnosis of hypoparathyroidism","volume":"101","author":"Clarke","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"issue":"11","key":"2024012714090724500_jbmr4726-bib-0028","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1210\/jc.2019-01010","article-title":"Safety and efficacy of 5\u2009years of treatment with recombinant human parathyroid hormone in adults with hypoparathyroidism","volume":"104","author":"Mannstadt","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2024012714090724500_jbmr4726-bib-0029","doi-asserted-by":"crossref","first-page":"5601","DOI":"10.1210\/jc.2019-00893","article-title":"Therapy of hypoparathyroidism with rhPTH(1\u201384): a prospective, 8-year investigation of efficacy and safety","volume":"104","author":"Tay","year":"2019","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jbmr.4726","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jbmr.4726","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/38\/1\/14\/55456317\/jbmr4726.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/38\/1\/14\/55456317\/jbmr4726.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T10:46:28Z","timestamp":1710326788000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/38\/1\/14-25\/7500057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,1]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,10,21]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.4726","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742376130.793596704","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.742376130.793596370","asserted-by":"object"}]},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12,1]]},"published":{"date-parts":[[2020,12,1]]},"assertion":[{"value":"2022-06-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}